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Background: It is known that the MDM2 protein is stabilized when it forms a heterodimer with its partner MDM4,
but MDM2 protein stability in its homodimer form is not known. The MDM2 protein contains a C-terminal RING domain
that not only functions as an E3 ligase to regulate ubiquitination of p53 and MDM2 itself, but also is characterized to
be able to bind several specific cellular mRNAs to regulate gene expression. In this study, we evaluate whether the
MDM2 protein stability is regulated by the binding of a specific small RNA (XIAP IRES mRNA).
Methods: We performed chemical cross-linking and bimolecular fluorescence complementation (BiFC) assay to measure
the human MDM2 protein stability in its homodimer form and the effect of XIAP IRES on MDM2 homodimerization and
protein stabilization. Ubiquitination and pulse-chase assays were used to detect MDM2 self-ubiquitination and protein
turn-over. Fluorescent titration and ITC were used to examine the binding between MDM2 RING protein and XIAP IRES.
Western blot assay was used for determining protein expression. Clonogenic assay, WST and flow cytometry were used
to test the effects of XIAP IRES, siXIAP and IR on cancer cell growth and apoptosis.
Results: We found that self-association (homodimerization) of MDM2 occurs through the C-terminal RING domain of
MDM2 and that the MDM2 protein becomes unstable when it is homodimerized. MDM2 homodimerization resulted in
an increased function of the RING domain for MDM2 self-ubiquitination. Binding of XIAP IRES to the RING domain inhibited
MDM2 homodimerization and self-ubiquitination, which resulted in stabilization of MDM2, as well as increased XIAP
expression. Upregulation of XIAP and MDM2 that led to inhibition of p53 by the XIAP IRES resulted in cell growth and
survival in both p53-normal and -deficient cancer cells.
Conclusions: Our study identified a new IRES RNA that interacts with MDM2 protein and regulates its stabilization,
which suggested that targeting of MDM2 through disruption of MDM2 protein-RNA interaction might be a useful
strategy for developing novel anti-cancer therapeutics.
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The MDM2 gene is an oncogene that is amplified in many
human cancers [1]. Also, high levels of MDM2 expression
can be observed even in malignancies without MDM2
gene amplification, as occurs in leukemia [2]. In cancer
patients, MDM2 overexpression is associated with disease
progression and poor treatment outcome [3-6].* Correspondence: mzhou@emory.edu; lbgu@emory.edu
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the tumor suppressor p53 [7-9]; thus, p53 function be-
comes inactivated in MDM2-overexpressing cells, result-
ing in cancer cell growth and disease progression.
MDM2 also plays p53-independent roles in oncogenesis.
Increasing evidence suggests that even in p53-deficient
cancer patients, MDM2 overexpression is still involved
in cancer promotion and progression, plus resistance to
treatment [10]. This is because in addition to interacting
with and regulating p53, MDM2 interacts with other
molecules involved in oncogenesis. For instance, MDM2s is an Open Access article distributed under the terms of the Creative Commons
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ing many p53-independent roles in cancer pathogenesis.
MDM2 expression is regulated in multiple ways: via gene
amplification, transcriptional induction by p53, and regula-
tion at the post-translational level by a self-ubiquitination
mechanism. MDM2, a member of the RING-finger-type
family of E3 ubiquitin ligases, is also a substrate of its own
RING domain E3 ligase [17]. Under certain conditions,
such as upon binding its partner MDMx (MDM4) and
nucleic acids or p53 mRNA, the capacity of the MDM2
RING domain to target itself for ubiquitination becomes
inhibited [18-20].
XIAP is an important member of the inhibitor of apop-
tosis protein (IAP) family. The XIAP protein binds specif-
ically to and inhibits the activated forms of caspases 3, 7
and 9, the enzymes that induce the intrinsic (mitochon-
drial) apoptotic pathway, which is the major cell death
mechanism that is induced by radiotherapy and many
chemotherapy drugs [21]. Specific inhibition of these cas-
pases by the XIAP protein suggests that this molecule is
critical for regulating sensitivity to anti-cancer treatment.
In fact, it is reported that upregulated XIAP is detected in
many cancer patients and that a high level of XIAP ex-
pression is associated with resistance to chemotherapy
and a poor prognosis [22-26]. The expression of the XIAP
protein is uniquely regulated by an IRES-dependent
mechanism at the translational level [27]. IRES-dependent
translation of XIAP becomes specifically activated when
cells undergo stress, such as during chemotherapy [28].
We previously found that the MDM2 RING domain
protein binds to the XIAP IRES RNA, increasing IRES-
mediated XIAP translation, which results in increased
expression of XIAP and resistance to anticancer treat-
ment [12]. In the present study, we evaluated whether
the expression of MDM2, in particular the E3 ubiquitin
ligase activity of MDM2 RING domain, is affected by its
binding with the relatively small XIAP IRES RNA. We
found that binding of XIAP IRES to the MDM2 RING
domain protein inhibited its ability for self-association
and self-ubiquitination, which increased MDM2 protein
stabilization and cancer cell survival.
Results
MDM2 is unstable in homodimer form
Previous studies demonstrate that MDM2 is able to
form a heterodimer with MDM4, and that the MDM2
protein is stabilized in the heterodimer [18]. How the
protein stability of MDM2 is regulated in its homodimer
form is not known. Chemical cross-linking with reagents
such as DSS is widely and typically used for protein
homodimerization [29]. We used DSS to treat either the
neuroblastoma cell line NB-1691 and LA1-55N, having
endogenous MDM2 expression, or SK-N-SH having a
transfected MDM2 to study MDM2 homodimerizationand to evaluate whether homodimerization affects the
level of MDM2 protein expression.
Western blot results in both NB-1691 (wt-p53) and
LA1-55N (p53-null) cells treated with DSS showed that
the expression of MDM2 protein in both the homodimer
and monomer forms was significantly reduced or even
non-detectable in LA1-55N (Figure 1A). In contrast, the
expression levels of MDM4, p53, XIAP and GAPDH in
the same cells that were similarly treated with DSS did not
become reduced. The data in Figure 1B represent the
dose–response expression levels for MDM2 and MDM4
after treatment with DSS; which showed a remarkable
downregulation of MDM2 but not MDM4 in their dimer
forms, by DSS cross-linking. These results suggested that
the MDM2 protein is unique in that it becomes unstable
when it forms a homodimer.
DSS cross-linking in SK-N-SH cells transfected with
MDM2 further confirmed that homodimerization causes
MDM2 protein instability. We transfected wt-MDM2 and
various mutated or deleted MDM2 fragments in SK-N-SH
cells and then treated with DSS. Results indicated that
DSS-induced homodimerization of the full-length (1–491)
MDM2 and the RING domain (415–491), but not MDM2
molecules with a RING domain deletion (1–424), nor the
RING domain having a deletion of the last 11 amino acids
(415–480) (Figure 1C). This suggested that the last 11
amino acids are a key region for MDM2 self-association.
Moreover, we found that homodimerization resulted in
reduced protein levels of wt full-length MDM2 (Figure 1C,
lane 2), while a full-length MDM2 with a mutation at 464
was reduced less (Figure 1C, lane 4). Cells with only a
homodimerized MDM2 RING domain showed no de-
creased protein level (Figure 1C, lane 8), suggesting that
MDM2 only degrades if homodimerized and if the full-
length protein is available as the RING domain ligase sub-
strate. There was less reduction of MDM2 when the 464
mutation, which provides loss of ubiquitin activity [30],
was present in the homodimer. This suggested that
MDM2 degradation in the homodimeric condition is likely
due to self-ubiquitination. In addition, when we performed
a co-transfection of the full-length MDM2 (tagged by Myc)
and the RING domain of MDM2 (tagged by HA), we
found that the increase in the RING domain of MDM2
decreased the transfected full-length MDM2 protein ex-
pression (Figure 1D) and stability (Figure 1E). In contrast,
co-transfection of the 464-mutated MDM2 RING protein
or the MDM4 RING domain did not decrease or even en-
hanced (co-transfection of MDM4) the expression of the
transfected full-length MDM2 (Figure 1D and F). These
results further suggested that homodimerization of the
MDM2 RING domain protein resulted in instability of the
full-length MDM2, while heterodimerization forming the
MDM2/MDM4 RING complex stabilized the full-length
MDM2.
Figure 1 Effect of homodimerization on MDM2 protein stability. A, homodimerization by DSS (0.5 mM) cross-linking for 30 min, with subsequent
expression of proteins as indicated, in their monomer and homodimer forms in NB-1691 and LA1-55N cells were detected by Western blot assays. B,
dose–response expression of MDM2 and MDM4 proteins after treatment with increasing concentrations (0.25, 0.5 and 1 mM) of DSS. C, homodimerization
by DSS and expression of transfected HA-tagged full-length MDM2 and various mutated or deleted MDM2 fragments in SK-N-SH cells, as detected by
Western blot using anti-HA (tagged) antibody. D, SK-N-SH cells were co-transfected with consistent amounts (3 μg) of Myc-tagged full-length MDM2
(Myc-MDM2/1–491) and increasing amounts (1, 2 and 3 μg) of either HA-tagged wt-RING domain of MDM2 (HA-MDM2/415–491) or 464 mutated
(464 m) RING domain of MDM2. The expression of transfected full-length MDM2 and the RING domains of MDM2 was detected by Western blot, using
anti-Myc and anti-HA antibodies, respectively. E, turnover of transfected MDM2 (as detected by anti-Myc antibody) in SK-N-SH cells, in the presence or
absence of HA-MDM2/415–491, as detected by pulse-chase assay. Numerical labels under each MDM2 band represent their relative expression levels
after normalization for GAPDH, as compared with untreated (0) samples that were defined as 1 unit. F, a similar co-transfection and Western blot assay
as described in (D) for the Myc-tagged full-length MDM2 and the HA-tagged RING domain of MDM4 (421–490).
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inhibits MDM2 homodimerization and self-ubiquitination
Previous studies show that binding of nucleic acids, such
as polyG, and p53 mRNA to the RING domain of MDM2
interfere with the ability of MDM2 to form homomeric
complexes and the protein stabilization [19,20]. We inves-
tigated whether XIAP IRES binds to the MDM2 RING do-
main and inhibits MDM2 homodimerization and protein
stability. We previously demonstrated the binding of XIAP
IRES RNA to the MDM2 RING domain by using 32P-la-
belled probes and a RNA-binding assay [12]. In the
present study, we performed fluorescent titration and ITCanalyses that verified that XIAP IRES RNA indeed binds
to the RING domain of MDM2 with high affinity. The
GST-MDM2 RING (415–491) fusion protein has natural
fluorescence, with an excitation of 280 nm and an emis-
sion of 335 nm (Figure 2A). We titrated the small XIAP
IRES to the MDM2 RING protein: Results showed a Kd of
0.68 μM for the binding (Figure 2B). We also titrated to
the MDM2 RING domain with several control RNAs
including a non-IRES upstream XIAP 5′-UTR fragment
[12], a mutated XIAP IRES and MYCN IRES, and no
binding activities were detected between MDM2 and
these RNAs. A similar Kd value of 0.7 μM for the binding
Figure 2 Determination of XIAP IRES RNA binding to MDM2 C-terminal RING domain protein. A, excitation and emission spectra of the
MDM2 RING domain protein. B, fluorescence intensity (FI) calculation of MDM2 RING domain protein in the presence of increasing concentrations
of XIAP IRES RNA and control RNAs (XIAP non-IRES, XIAP IRES mutation and MYCN IRES), relative to the FI in the absence of RNA, to derive the Kd.
C, thermodynamic measurement of the binding of XIAP IRES RNA (left) and XIAP non-IRES (right) to MDM2 RING protein using isothermal titration
calorimetry (ITC). The upper box is the raw heating power over time and the lower box is a fit of the integrated energy values, normalized for
each injection. We performed each ITC experiment three times or more.
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results suggest that the binding between XIAP IRES and
MDM2 RING protein is specific.
Now, we investigated the effect of XIAP IRES binding to
the MDM2 RING protein on the homodimerization of
MDM2. We performed DSS cross-linking in SK-N-SH cells
transfected with the MDM2 RING domain, in the presence
or absence of XIAP IRES. Our results showed that XIAP
IRES, as well as polyG, inhibited the homodimerization of
the transfected MDM2 RING protein (Figure 3A). Similar
experiments in NB-1691 cells showed that XIAP IRES also
inhibited homodimerization of the endogenous full-length
MDM2, resulting in a reversal of the decrease in MDM2
levels following DSS treatment (Figure 3B).
In addition, we performed an in vivo bimolecular fluores-
cence complementation (BiFC) assay, where the MDM2
RING domain (415–491) was fused to the N (1 to 154)
and C (155 to 238) terminal halves of YFP. The RING
domain-mediated dimerization of two YFP fragments
should reconstitute a fluorescent protein, when co-
expressed in cells. As expected and shown in Figure 3C,
the YN-RING or YC-RING transfections alone did not
generate a signal, whereas co-transfection of the YN-RINGand YC-RING produced strong fluorescence with a
diffused localization in SK-N-SH cells. Meanwhile, XIAP
IRES, but not the XIAP non-IRES, significantly decreased
the fluorescence generated by the interaction of the YN-
RING and YC-RING.
Next, we performed in vitro ubiquitination assays,
finding that the self-ubiquitination activity of in vitro-
translated MDM2 was inhibited by XIAP IRES, as was
seen in the PolyG (positive control) reaction (Figure 3D).
As also seen in Figure 3D, mutations of MDM2 448 (loss
of RNA binding activity) [11] diminished the XIAP
IRES-mediated inhibition of MDM2 self-ubiquitination,
while the mutation of MDM2 428 (retains RNA binding
activity) [12] did not, suggesting that binding to the
MDM2 RING protein is essential for XIAP IRES to
affect MDM2 self-ubiquitination. Furthermore, we per-
formed co-transfection and in vivo ubiquitination assays
and results showed that the self-ubiquitination activity of
transfected MDM2 in SK-N-SH cells was inhibited by
XIAP IRES in a dose-dependent manner (Figure 3E). Mu-
tation analyses indicated that XIAP IRES failed to inhibit
self-ubiquitination of MDM2 448 mutation. Mutation of
464 lost ubiquitin activity. Although mutation of 428 had
Figure 3 XIAP IRES RNA inhibited MDM2 protein homodimerization and self-ubiquitination. A, the effects of XIAP IRES RNA and PolyG
(control) on the homodimerization of the MDM2 RING domain (415–491) in a co-transfection of SK-N-SH cells, as examined by DSS cross-linking.
GAPDH served as a control protein. B, XIAP IRES decreased homodimerization of endogenous MDM2 in NB-1691 cells, as detected by DSS treatment
and Western blot. C, Representative photographs of YFP fluorescence signal in SK-N-SH cells co-transfected with YFP N/C fragments fused to the
MDM2 RING domain (YN-RING/YC-RING) in the absence and presence of XIAP IRES mRNA and XIAP non-IRES (control RNA). D, XIAP IRES decreased
MDM2 self-ubiquitination, as examined by in vitro ubiquitination assays. The in vitro-translated (Ivt), 35S-labeled MDM2 was incubated under standard
ubiquitination conditions in the absence (−) and presence of either XIAP IRES or polyG (control). We added the bacterially-expressed wild-type (wt)
GST-MDM2 or GST-MDM2 mutated (428 or 448) fusion protein to the reactions and analyzed the reaction mixtures by SDS-PAGE, followed by
autoradiography. E, the in vivo ubiquitination assay for the effect of XIAP IRES RNA on MDM2 self-ubiquitination in SK-N-SH cells co-transfected
with 5 μg of each plasmid as indicated. Ni-NTA-purified, ubiquitinated MDM2 (upper) and transfected MDM2 (lower) from direct cell lysates
were analyzed by Western blot. Additional controls were transfections either without His-ub or without MG132 treatment. F, a similar in vivo
ubiquitination assay as in (E) to confirm the effect of XIAP IRES RNA on MDM2 self-ubiquitination in SK-N-SH cells transfected with different mutated
MDM2 plasmids as indicated.
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binding of XIAP IRES to this mutation further inhibited
its activity for self-ubiquitination (Figure 3F).
Enforced overexpression of XIAP IRES increases MDM2
expression and growth of cancer cells
Because binding of XIAP IRES to the MDM2 RING pro-
tein inhibited MDM2 homodimerization, which resulted in
inhibition of MDM2 self-ubiquitination, we evaluated the
cellular consequences of XIAP IRES-mediated inhibitionof MDM2 self-ubiquitination in cancer cells. We per-
formed a transfection of the plasmid pRNA-CMV3.1/XIAP
IRES, which constitutively produced XIAP IRES RNA, to
enforce overexpression of XIAP IRES in SK-N-SH cells.
Transfection of XIAP IRES increased MDM2 protein
expression, resulting in a concomitant decrease in p53
expression, in a dose-dependent manner (Figure 4A).
Overexpression of XIAP IRES also led to a dose-
dependent increase in XIAP expression, which we believe
is a result of increased MDM2 expression that led to
Figure 4 Effect of enforced overexpresson of XIAP IRES RNA on the expression of MDM2 and XIAP and on cancer cell growth. A, SK-N-SH
cells were transfected for 24 h with the indicated amounts of pRNA-CMV3.1/Puro XIAP IRES RNA or pRNA-CMV3.1/Puro XIAP non-IRES RNA (control
RNA) plasmids and the expression of MDM2, XIAP, MDM4 and p53 proteins was detected by Western blot. B, turnover of proteins as indicated in SK-N-SH
cells transfected with XIAP IRES RNA or control RNA, as detected by pulse-chase assay. C, SK-N-SH cells stably transfected with either XIAP IRES RNA or
control RNA expression plasmids were incubated in medium at an initial concentration of 104/ml and then counted every day. Data shown: total number
of cells (mean ± SD for triplicate cultures, *p< 0.05). D, clonogenic assay of MDM2 or vehicle-stably transfected SK-N-SH cells and siMDM2 or vehicle-stably
transfected SH-EP1 cells that were co-transfected with either XIAP IRES RNA or control RNA. We seeded and cultured 200 cells with or without RNA
transfection for 2 weeks, then stained the colonies and counted them under phase contrast microscopy. Data represent the mean of three independent
experiments (bars ± SD, *p < 0.05, **p > 0.5). E, representative plate pictures for colony formation of SK-N-SH cells transfected with or without
RNA expression plasmids as indicated.
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its translation activity. Turnover of both MDM2 and p53
after XIAP IRES transfection was measured by pulse-
chase assay. As shown in Figure 4B, transfection of XIAP
IRES increased the half-life of MDM2, which was followed
by enhanced degradation of p53. The turnover of XIAP
protein was not changed in XIAP IRES-transfected cells
as compared with control-transfected cells, suggesting
that the increased XIAP expression was not due to post-
translational modification.We measured and compared the growth rate of cancer
cells that were stably transfected with XIAP IRES with those
transfected with XIAP non-IRES. As seen in Figure 4C,
the XIAP IRES-transfected SK-N-SH cells exhibited an
increased growth rate, compared to control-transfected
SK-N-SH cells. We also performed clonogenic assays in
SK-N-SH cells stably-transfected with MDM2 and in SH-
EP1 cells stably-transfected with siMDM2, as previously
established [31], in the presence or absence of XIAP IRES.
XIAP IRES increased colony formation of either SK-N-
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SH-EP1 cells with MDM2 knockdown (Figure 4D and E),
suggesting that the effect of XIAP IRES on cancer cell
growth is MDM2-dependent.
Enforced overexpression of XIAP IRES increases resistance
to apoptosis
We examined the effect of XIAP IRES on cancer cell
apoptosis and death induced by knockdown of XIAP.
Since enforced overexpression of XIAP IRES enhanced
XIAP expression as well as MDM2 stabilization that led
to inhibition of p53, we selected both wt-p53 and p53-null
cancer cells and treated them with siXIAP, in order to
know whether both MDM2-p53 and XIAP signaling path-
ways are involved in the effect of XIAP IRES on cancer
cell survival and apoptosis. Cell lines SK-N-SH (wt-p53)Figure 5 Effect of enforced overexpresson of XIAP IRES RNA on cell a
were stably transfected with either XIAP IRES RNA or XIAP non-IRES RNA (c
48 h, and cell survival was determined by WST assays. Data represent the mea
*p < 0.05 (A), p > 0.5 (B). C, time-course of apoptosis induced by IR in SK-N-
IRES RNA or XIAP non-IRES RNA. Cells were treated with 10 Gy IR for the in
annexin-V staining and flow cytometry. Data represent the mean percenta
bars ± SD, *p < 0.01, **p < 0.05. D, same SK-N-SH and LA1-55N cells transfe
nM siXIAP alone or their combination for 24 h, and then apoptosis was deand LA1-55N (p53-null) were stably transfected with
XIAP IRES or XIAP non-IRES RNA (control) and then
treated with siXIAP. The siXIAP inhibited cell growth or
induced cell death, as detected by WST cytotoxic assay, in
both SK-N-SH and LA1-55N cells that transfected either
with XIAP IRES RNA or with control RNA (Figure 5A
and B). However, siXIAP induced more cell death in
wt-p53 SK-N-SH cells transfected with control RNA than
in the same cells transfected with XIAP IRES (Figure 5A),
whereas siXIAP induced almost same degree of cell death
in the p53-null LA1-55N cells transfected either with
XIAP IRES or with control RNA (Figure 5B). This sug-
gested that the XIAP IRES-mediated upregulation of
MDM2 and subsequently inhibition of p53 in SK-N-SH
cells plays a role in protection of the cells from death
induced by knockdown of XIAP.poptosis. A and B, SK-N-SH (wt-p53) and LA1-55N (p53-null) cells that
ontrol) were treated with different dose of siXIAP or control siRNA for
n percentage (±SD) of cell survival from three independent experiments,
SH and LA1-55N cells that were stably transfected with either XIAP
dicated time points, and then the apoptotic cells were detected by
ge of annexin-V positive cells from three independent experiments,
cted with RNA as described above were treated with 10 Gy IR or 200
tected as in (C), *p < 0.01, **p > 0.5.
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SH and LA1-55N cells transfected with XIAP IRES or
control RNA and treated with ionizing radiation (IR).
Similarly, IR induced much more apoptosis in wt-p53
SK-N-SH cells transfected with control RNA than in the
same cells transfected with XIAP IRES. In contrast to
siXIAP, IR also induced more apoptosis in p53-null LA1-
55N transfected with control RNA than in the same cells
transfected with XIAP IRES (Figure 5C), although the dif-
ference was smaller than that in SK-N-SH cells. Further-
more, we treated the same RNA-transfected SK-N-SH and
LA1-55N cells with a combination of IR and siXIAP. A
significant difference of apoptosis induction by the com-
bination treatment between XIAP IRES and control RNA
transfected cells was observed in the wt-p53 SK-N-SH
cells but not in the p53-null LA1-55N cells (Figure 5D).
As also seen in this figure, siXIAP seems to induce more
apoptosis in XIAP IRES-transfected and less in control
RNA-transfected cells, as compared to IR. Together, these
results suggest that XIAP IRES binding to the MDM2
protein indeed plays a role in regulation of apoptosis.
Discussion
MDM2 and XIAP are very important cancer-related fac-
tors: MDM2 acts as an oncoprotein, promoting cancer
progression mainly through inhibition of the tumor sup-
pressor p53; and as an anti-apoptotic protein, XIAP
plays a critical role in the development of resistance to
anticancer treatment via inhibition of therapy-induced
caspases. Our studies demonstrated a mutual regulation
of MDM2 protein and XIAP mRNA in cancer cell
growth and disease progression. We previously showed that
the RING domain of the MDM2 protein binds to the XIAP
IRES mRNA, increasing IRES-mediated XIAP translation,
which results in increased expression of XIAP and resist-
ance to anticancer treatment [12]. In the present study, we
characterized the XIAP IRES bound to the MDM2 RING
domain protein, finding that the combination inhibited
MDM2 homodimerization, self-ubiquitination and degrad-
ation. Enforced overexpression of the XIAP IRES RNA in
cancer cells increased the expression of both MDM2 and
XIAP, which led to cancer cell survival and resistance to
apoptosis.
While the regulation of XIAP expression is well char-
acterized at the translational level [27], the expression of
MDM2, in particular in cancer cells, is not fully under-
stood. Previous studies demonstrate that the expression
of MDM2 is regulated at multiple levels. Overexpression
of MDM2 due to genomic amplification occurs in a var-
iety of solid human cancers [1]. In addition, overexpres-
sion of MDM2 is detected in many malignancies, such
as leukemia, that lack MDM2 gene amplification [2]:
The mechanism by which MDM2 is overexpressed in
cancers in the absence of gene amplification is notcompletely known. Previous studies demonstrate that
MDM2 overexpression in cancer cells is frequently asso-
ciated with a wt-p53 phenotype [32,33]. Because MDM2
is a transactivational target of wt-p53, increased MDM2
expression could be a direct response to wt-p53 activity
[34]. In some cancers, high levels of MDM2 expression
occur due to a single nucleotide polymorphism (snp) in
the MDM2 gene promoter [35]. Whether high-level
MDM2 expression is also associated with the regulation
of MDM2 protein stability in cancer is less understood.
MDM2 is an unstable protein that becomes ubiquiti-
nated and degraded in an autocatalytic manner [17,36];
however, an increase in protein stability of MDM2 can
be brought about by the binding of many cellular mole-
cules to the C-terminal RING domain of the MDM2
protein. For example, the MDM2 homolog MDM4 binds
to MDM2 through their respective RING domains,
which increases MDM2 protein stabilization [18]. DAXX
and HAUSP interact with MDM2 to form a tertiary
complex, which reduces self-ubiqitination of MDM2
[37]. Nucleic acids, such as polyA or polyG, also can
bind to the MDM2 RING domain and inhibit MDM2
homodimerization, as well as the capacity of MDM2 to
target itself for ubiquitination [19]. The MDM2 protein
stability is also regulated by a poly-ubiquitination mech-
anism. A recent study by Huang et al. showed that
MDM2 is ubiquitinated by XIAP E3 ligase, leading to
MDM2 degradation, which is involved in inhibition of
autophagy, probably contributing to tumorigenesis [38].
In contrast, in the present study we found that XIAP
mRNA positively regulates MDM2. We demonstrated
that binding of XIAP mRNA to the RING domain of
MDM2 stabilized MDM2. The expression of MDM2
protein positively regulated by mRNA binding has been
previously reported by Candeias et al., who showed that
binding of p53 mRNA to the RING protein of MDM2 in-
creased MDM2 expression [20]. Our studies using trans-
fection to enforce XIAP IRES overexpression in cells
further characterized that the XIAP IRES-mediated in-
crease in MDM2 protein expression is through the inhib-
ition of MDM2 homodimerization, resulting in a reduction
of the E3 ubiquitin ligase activity of the C-terminal RING
domain that is used by MDM2 to target itself for ubiquiti-
nation and degradation. The XIAP mRNA and protein
reciprocally regulate MDM2 protein stability through
different mechanism, which is likely a homeostasis for
MDM2 expression, suggesting that the interaction of the
two factors and their deregulation may play a critical role
in cancer pathogenesis.
Upon MDM2 homodimerization or its heterodimeriza-
tion with MDM4, MDM2 exhibits increased E3 ubiquitin
activity as compared with being in its monomer form [39].
The increased E3 activity in MDM2 homodimers is
thought to function primarily in inducing MDM2 self-
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form, one MDM2 molecule might act as a substrate,
while the other one acts as the E3 enzyme to induce self-
ubiquitination and degradation [40]. This notion was
supported by our experimental results shown in Figure 1,
in which self-association of MDM2 by cross-linking re-
duced the protein levels, and particularly, the expression
and half-life of the transfected full-length MDM2 de-
creased by co-transfection of the MDM2 RING domain.
In a heterodimer, the MDM2 RING domain induces
ubiquitination of MDM4, but not itself [40]; although
the mechanism for this selective ubiquitination is not
known. Our results showed that co-transfection of the
MDM4 RING domain with the full-length MDM2 did not
reduce and even enhanced expression of the transfected
full-length MDM2 (Figure 1E), which is consistent with a
previous report that MDM2 becomes stabilized when
heterodimerized with MDM4 [18].
Because the MDM2 RING domain in a heterodimer
with MDM4 induces ubiquitination and degradation of
MDM4, XIAP IRES RNA binding to the MDM2 RING
domain might not only disrupt the formation of MDM2
homodimers, but also block the interaction between
MDM2 and MDM4 that stabilizes both MDM2 and
MDM4, leading to potent inhibition of p53 activity. In
fact, we detected increased expression and prolonged
half-life of MDM4 in enforced XIAP RNA-overexpressing
cells (Figure 4A and B).
Because MDM2 is an important inhibitor of the tumor
suppressor p53, and because the overexpression of
MDM2 occurs in a variety of cancers, many efforts have
been made to target the MDM2-p53 interaction, in
order to prevent its apparent promotion of cancer and
improve the power of anticancer therapies. So far, small-
molecule inhibitors such as nutlin-3 and MI-219 were
identified as able to efficiently block the interaction be-
tween MDM2 and p53, resulting in not only activation
of p53, but apoptosis of cancer cells [41,42]; however, a
limiting factor is that these small-molecule inhibitors ex-
hibit their beneficial cytotoxic and apoptotic effects only
in cancer cells bearing normal p53. Furthermore, these
molecules do not inhibit MDM2, so the expression of
MDM2 was even remarkably enhanced in either nutlin-
3 or MI-219 -treated cells [41,42], which might still
exhibit any p53-independent cancer-promoting roles,
such as inducing XIAP, to diminish or even abrogate the
apoptotic activity of a given small-molecule inhibitor.
In fact, a previous study has demonstrated that con-
comitant inhibition of MDM2 by nutlin-3 and of XIAP by
small molecule antagonists synergistically induced apop-
tosis in wt-p53 leukemia cells [43]. Our studies including
previous one [12] identify the binding between the
MDM2 RING domain and XIAP IRES RNA that simul-
taneously increases expression of XIAP and MDM2,which provides an excellent molecular target to develop
an alternative/innovative strategy for cancer therapeutics.
In fact, blocking or disrupting the interaction between the
MDM2 RING protein and XIAP IRES RNA by a specific
antisense leads to inhibition of cancer cell growth and in-
creased apoptosis [12]. Due to limitations in the clinical
application of antisense, discovery of small-molecule com-
pound inhibitors to block the interaction between MDM2
RING protein and XIAP IRES RNA would be very inter-
esting. Once such inhibitors are identified, we believe that
they will be able to induce much more potent apoptosis
than what nutlin-3 or MI219 can: In normal p53-carrying
cancer patients, treatment with a compound producing
the simultaneous inhibition of MDM2 and XIAP should
result not only in the activation of p53, but also in induc-
tion of caspases 3, 7 and 9. Most importantly, the same
MDM2/XIAP inhibitors will almost certainly be able to
induce apoptosis in p53-deficient cancer cells, if those
cells express both MDM2 and XIAP.
Methods
Cell lines and reagents
In this study, four human neuroblastoma cell lines
(NB-1691, SH-EP1, SK-N-SH and LA1-55N) were
used. As previously characterized, NB-1691, SH-EP1
and SK-N-SH are wild-type (wt) p53 and LA1-55N is
p53-null. NB-1691 and SH-EP1 have MDM2 overex-
pression, while SK-N-SH and LA1-55N have low levels of
MDM2 expression [14]. These cell lines were obtained
from Dr. H. Findley (Emory University) and grown in
standard culture medium (RPMI 1640 containing 10%
FBS, 2 mmol/L of L-glutamine, 50 units/ml penicillin and
50 μg/ml streptomycin) in incubators set at 37°C with 5%
CO2 in air.
MDM2 antibody (SMP14) was purchased from Sigma;
p53 (DO-1) was purchased from Santa Cruz; XIAP (2F1)
was purchased from Abcam. MDM4 (2D10F4) antibody
was purchased from LifeSpan BioSciences. The concen-
trations of all antibodies were used according to the
manufacturers’ instruction.
Plasmids and transfection
The HA or Myc-tagged wt and various truncated or
mutated human MDM2 constructs were generated by
polymerase chain reaction (PCR) and cloned them into
pCMV-HA or pCMV-myc expression vectors (Clontech).
A Quick Change Site-Directed Mutagenesis Kit (Strata-
gene) was used to mutate the MDM2 464 (substitution of
Cys by Ala) and MDM2 448 (mutation of Gly to Ser), to
generate plasmids that exhibited loss of E3 ligase [30] and
RNA binding [11] activities, respectively. A MDM2 428
mutation (change of Ser to Gly) plasmid was generated as
control. We also generated the GST-tagged, full-length
MDM2 (wt and mutated) and the MDM2 C-terminal
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into the bacterial pGEX expression vector. The YN-RING
and YC-RING plasmids were generated by fusing the
MDM2 C-terminal RING domain into the YFP/1-154
(YN) and YFP/155–238 (YC) regions, respectively, of the
yellow fluorescent protein (YFP) plasmid that was pro-
vided by Dr. J. Cheng (Moffitt Cancer Center). To gener-




AGAAAAATCTTTTCCACCTTCGA-3′ that contains the
fragment from-34 to-62 of the XIAP 5′-UTR, which is the
RNP core binding site and is bound by MDM2 [12,27], and
then inserted them immediately downstream of the CMV
promoter of the pRNA-CMV3.1-puro vector (Genscript,
Piscataway, NJ). A control RNA plasmid was generated
similarly by annealing the primers containing 28-nt of
non-IRES upstream 5′-UTR of XIAP mRNA (sequence
not shown) and inserting to pRNA-CMV3.1-puro vec-
tor. The pCI-His-hUbi plasmid was purchased from
Addgene. Transfection of various MDM2 constructs and
XIAP IRES plasmids into NB cell lines was performed in
6-well plates, using Lipofectamine™ 2000 reagents (Invi-
trogen) according to the manufacturer’s instructions.
The siXIAP and control siRNA were purchased from
Santa Cruz, and transfection of siRNA was carried out
using the HiPerFect transfection reagent (Qiagen), fol-
lowing the manufacturer’s manual.
Chemical cross-linking
Chemical cross-linking was performed using previously-
described methods [44]. Briefly, cells with or without
transfection of various MDM2 constructs were har-
vested and rinsed twice with cold PBS. The cell suspen-
sion was incubated with disuccinimidyl suberate (DSS,
20 μl of 25 mM stock solution in DMSO per 1 ml cell
suspension). For the preparation of mock lysates, DMSO
without DSS was added to the cells. Cross-linking was
carried out for 30 min at room temperature, followed by
quenching of the cross-linking with Tris-buffered saline
(TBS at 25 mM, pH 7.5) for 15 min, and then cells were
lysed and analyzed by Western blot.
Immunoprecipitation and Western blot assay
Cells were lysed in a buffer composed of 50 mM Tris,
pH 7.6, 150 mM NaCl, 1% Nonidet P-40, 10 mM sodium
phosphate, 10 mM NaF, 1 mM sodium orthovanadate,
2 mM phenylmethylsulfonyl fluoride (PMSF), 10 μg/ml
aprotinin, 10 μg/ml leupeptin and 10 μg/ml pepstatin.
After centrifugation, the clarified cell lysate was separated
from the pellet of cell debris and then incubated it over-
night at 4°C with 15 μl Protein G plus/Protein A-agarose
and 1 μg of antibodies. For Western blot, the resulting celllysates or immunoprecipitates were resolved by sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE), then the gel contents were transferred to a nitro-
cellulose filter and probed with specific antibodies, finally
protein expression levels were visualized with a chemilu-
minescent detection system (Pierce).
Bimolecular fluorescence complementation (BiFC) assay
The YN-RING and YC-RING fusion plasmids that con-
tain the MDM2 RING domain, along with or without
pRNA-CMV-XIAP IRES, were co-transfected into SK-N-
SH cells, using Lipofectamine 2000 reagents for 24 h.
The cells were cultured at 30°C for 10 h to allow matur-
ation of the fluorophore, and then counted the MDM2
RING dimer-positive cells with visible YFP fluorescence
and executed a comparison, in a blinded fashion, of the
different samples.
In vitro and in vivo ubiquitination assays
For in vitro ubiquitination assay, the full-length GST-
MDM2 (wt and various mutations) was expressed and
purified as previously described [12]. The substrate
MDM2 was produced by in vitro translation in rabbit
reticulocyte lysate, using the TNT system (Promega), in
the presence of [35S] methionine. The in vitro ubiquiti-
nation assay was performed in a total reaction volume of
50 μl, consisting of 1 μl 35S-labeled substrate MDM2,
50 ng E1, 50 ng UbcH5, 10 μg ubiquitin and 500 ng
GST-MDM2; in the absence or presence of XIAP IRES
RNA that was prepared as previously described [12], in a
buffer containing 25 mM Tris–HCl (pH 7.5), 100 mM
NaCl, 1 mM dithiothreitol, 2 mM ATP and 4 mM MgCl2.
After a 2-h incubation at 30°C, the mixture in SDS sample
buffer was boiled, fractionated it by SDS-PAGE, and then
detected by autoradiography.
For in vivo ubiquitination assay, cells were co-
transfected with the plasmids for MDM2, His6-ubiquitin
and XIAP IRES. After a 24-h incubation, the cells were
treated with (or without) MG132 for an additional 6 h,
and then the cells were collected from each transfection
into two aliquots. One aliquot (10%) was used for con-
ventional Western blotting to confirm the transfected
MDM2 was expressed. The remaining cells (90%) were
used for the purification of His6-tagged MDM2, with
the aid of Ni2+-nitrilotriacetic acid beads, as previously
described [45]. This His-tagged MDM2 was then eluted
and analyzed by Western blot assay.
Protein and RNA binding assays
Fluorescent titration and isothermal titration calorimetry
(ITC) assays were carried out to confirm the binding of
XIAP IRES RNA to the MDM2 RING domain protein.
The GST-MDM2 RING (415–491) fusion protein has
natural fluorescence, with an excitation of 280 nm and
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RNAs including a non-IRES upstream XIAP 5′-UTR
fragment, a mutated XIAP IRES and MYCN IRES (the
sequences of these RNAs as described previously [12,14]
were titrated to MDM2 RING domain protein. The tested
RNAs were placed in the same buffer containing the
MDM2 RING protein, so that the protein concentration
was kept constant during titration. The steady-state fluor-
escence of the protein-RNA mixtures were acquired on a
PTI Quanta-Master spectrometer (Photon Technology
International, Birmingham, NJ), using a 3 ml cuvette. The
slit widths for excitation and emission were adjusted to
minimize any photobleaching of the sample, while
achieving sufficient fluorescent signal intensity. The
fluorescence measurements, as a function of RNA con-
centration, were fitted with the hyperbolic function F = Ff +
(Fb − Ff) [ligandf]/(Kd + [ligandf]), where F is the observed
fluorescence, Ff is the fluorescence of unbound protein, Fb
is the fluorescence from the protein-RNA complex, ligandf
is the concentration of the RNA, and Kd is its dissociation
constant.
For the ITC assay, 20 μM of MDM2 RING protein
was placed in a 400 μl buffer containing 10 mM Hepes
at pH 7.2 and 150 mM NaCl, in a loading 96 DeepWell
PP plate (Nunc, Thermo Fisher Scientific). A 10-fold
concentration of XIAP IRES RNA (200 μM) in 120 μl of
the same buffer was automatically transferred by the
auto-ITC200 instrument (MicroCal, GE) into the sample
cell. RNA solution (2 μl) was titrated stepwise into the
protein sample cell using a syringe, for a total of 16
injections (except that the first injection was 0.4 μl). The
equilibrium time between two adjacent injections was
210 s. We determined the binding stoichiometry (n),
binding constant (Kd), and thermodynamic parameters
(ΔH and ΔS) by fitting the titration curve to a one-site
binding mode, using Origin software provided by the
manufacturer.
Pulse-chase assay
The protein turnover was assessed by a standard
protein-synthesis inhibitor cycloheximide (CHX) assay.
Briefly, cells were treated with 50 μg/ml CHX for differ-
ent times before lysis, in the presence or absence of anti-
sense or siRNA transfection. The concurrent expression
levels of tested proteins were analyzed by Western blot
as described above.
Cell growth rate and clonogenic assays
For the growth rate test, cells were cultured in medium at
an initial concentration of 104/ml, using a total of 21
plates for each condition. Cells were counted each day,
using a hemocytometer under a light microscope, in three
(calculation of mean ± SD) of the 21 plates, so the growth
rate could be determined after 7 days. A clonogenic assayto measure colony formation was used according to a
previously described method [46]. Briefly, cells were
harvested with treatment by trypsinization, producing a
single-cell suspension, and then 200 cells were seeded into
a 6-well plate and cultured for about 2 weeks. The col-
onies were stained with a mixture of 6.0% glutaraldehyde
and 0.5% crystal violet for about 30 min, then carefully
removed and rinsed with tap water. After that, the
colonies were counted and calculated.
WST assay
The cytotoxic effect of siXIAP on ALL cells was deter-
mined using the water-soluble tetrazolium salt (WST)
assay. Briefly, cells cultured in 96-well microtiter plates
were given different concentrations of siXIAP, for a
48-h period. Following this, WST (25 μg/well) was
added and incubation continued for an additional 4 h
before the optical density (OD) of the wells was read
with a microplate reader (set at a test wavelength of
450 nm and a reference wavelength of 620 nm). Appro-
priate controls lacking cells were included, to determine
background absorbance.
Flow cytometry
For the quantitative detection of apoptotic cells, we per-
formed annexin-V staining followed by flow cytometry.
Cells with or without treatment were harvested and washed
once with PBS, and then stained with FITC-annexin-V and
PI, according to the manufacturer’s instructions. The cells
were analyzed by flow cytometry.
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